• Blog
  • SGLT2 Inhibitor Market Report

    SGLT2 Inhibitor Market Report

    SGLT2 Inhibitor Market Report
    Report code - SRHL280 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global SGLT2 Inhibitor Market, Dynamics, and Market Analysis
    See more...

    Impact of COVID-19 on SGLT2 Inhibitor Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on SGLT2 Inhibitor Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global SGLT2 Inhibitor Market is expected to grow from USD xx million in 2020 to USD xx million by 2026 at a CAGR of over x% during the forecast period.

    Figure: Global SGLT2 Inhibitor Market Size, 2020-2026 (USD Million)

    SGLT2-Inhibitor-Market-Forecast

    Wish to learn more about this study? Click here to get a free sample report.

    What is SGLT2 inhibitor?

    SGLT2 inhibitor is a new oral medication used for treating type 2 diseases which include dapagliflozin, canagliflozin, empagliflozin, and others. It works by preventing the kidneys from reabsorbing glucose back into the blood. It blocks these proteins and helps the kidneys to lower blood glucose levels. The excess glucose in the blood is passed out by the body via urine.

    Key Players

    Key players operating in the global SGLT2 Inhibitor Market are-

    • Eli Lilly and Company (The U.S),
    • C.H. Boehringer Sohn AG & Ko. KG (Germany),
    • Johnson & Johnson (The U.S),
    • AstraZeneca plc (UK),
    • The Merck Group (Germany),
    • Pfizer Inc. (The U.S),
    • Tecnimede Group (The U.S),
    • Unichem Laboratories Ltd. (India), and
    • Edifício Bluepharma (Portugal).

    Market Dynamics

    The growth of the global SGLT2 Inhibitor market is primarily driven by an increasing number of people suffering from diabetes.

    • Changing lifestyle, overweight and obesity are some of the leading causes of diabetes.
    • Growing demand for simple and more effective methods to treat diabetic problems is likely to drive the market growth at a substantial rate during the review period.
    • Growing emphasis on new drug development with the more effective result is expected to create lucrative opportunities for the players operating in the global SGLT2 inhibitor market. 

    Segment Analysis

    Type Trends

    Based on type, the market has been segmented into dapagliflozin, canagliflozin, empagliflozin and other.

    • The canagliflozin segment accounted for the largest market share in 2020 due to its widespread usage and availability of very few generic brands for this drug in the market.
    • The consumption of these drugs depends on their associated side effects.  

    Regional Trends

    Geographically, the market in North America accounted for the largest market share in 2020.

    • The regional market growth can be attributed to high adoption of advanced solutions in the hospitals.
    • Additionally, rising incidences of diabetes is projected to fuel the product demand further.
    • The market in Asia-Pacific is expected to grow at a fastest CAGR during the review period on account of increasing prevalence of various chronic diseases and rising healthcare spending.

    COVID-19 Impact on Global SGLT2 Inhibitor Market

    The covid-19 outbreak affected the growth of the SGLT2 Inhibitor market short period of time as due to supply chain disruptions amid lockdown; the product availability in the market was hampered. Covid-19 also affected the cardiovascular care of the patients despite no infection, which resulted in increased demand for SGLT2 inhibitor as it helps treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes.

    Critical Questions Answered in the Report

    • What are the key trends in the global SGLT2 Inhibitor market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global SGLT2 Inhibitor market?
    • What are the key strategies adopted by the major vendors to lead in the global SGLT2 Inhibitor market?
    • What is the market share of the top vendors?

    To know about the assumptions related to the report, Register Here

    Target Audience

    Here is the list of the group of customers that the SGLT2 Inhibitor market hopes to have the greatest opportunity to convert-

    • SGLT2 Inhibitor manufacturers
    • SGLT2 Inhibitor suppliers
    • SGLT2 Inhibitor distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    Eli Lilly and Company (The U.S), C.H. Boehringer Sohn AG & Ko. KG (Germany), Johnson & Johnson (The U.S), AstraZeneca plc (UK), The Merck Group (Germany), Pfizer Inc. (The U.S), Tecnimede Group (The U.S), Unichem Laboratories Ltd. (India) and Edifcio Bluepharma (Portugal) are among the key players in the SGLT2 inhibitor market.

    North America accounted for the largest share in the SGLT2 inhibitor market in 2020.

    Asia-pacific is expected to grow at the fastest CAGR in the SGLT2 inhibitor market during the forecast period.

    The canagliflozin segment accounted for the largest share in the SGLT2 inhibitor market in 2020.

    Increasing number of people suffering from diabetes, growing demand for simple and more effective methods to treat diabetic problems, growing emphasis on new drug development with the more effective result are the factors driving the growth of SGLT2 inhibitor market.

    SGLT2 Inhibitor manufacturers, SGLT2 Inhibitor suppliers, SGLT2 Inhibitor distributors, Organizations, Government bodies are the target audience in the SGLT2 inhibitor market.

    •